Subject: Tresiba ST, Post PA (Aetna SG ACA, IVL Only) Policy 4773-D UDR 05-2023

Drug

TRESIBA (insulin degludec)

Policy:

FDA-APPROVED INDICATIONS

Tresiba is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Not recommended for the treatment of diabetic ketoacidosis.

INITIAL STEP THERAPY*

*Include Rx and OTC products unless otherwise stated.

If the patient has filled a prescription for at least a 30-day supply of Basaglar (insulin glargine) or Levemir (insulin detemir) within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has experienced an inadequate treatment response to Basaglar (insulin glargine) OR Levemir (insulin detemir)
- The patient has experienced an intolerance to Basaglar (insulin glargine) OR Levemir (insulin detemir) OR
- The patient has a contraindication that would prohibit a trial of Basaglar (insulin glargine) AND Levemir (insulin detemir)

Duration of Approval (DOA):

· 4773-D: DOA: 12 months

Place of Service:

Outpatient

The above policy is based on the following references:

1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; July 2022.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

October 14, 2023